Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer-Reference-Cited by-同舟云学术

Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer

Published:2023-08-14 Issue:16 Volume:149 Page:14597-14617
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Ma Peng,Sun Weili

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-023-05268-y.pdf

Reference52 articles.

1. Banta KL, Xu X, Chitre AS et al (2022) Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses. Immunity 55:512–526. https://doi.org/10.1016/j.immuni.2022.02.005. (e519)

2. Bonneville R, Krook MA, Kautto EA et al (2017) Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. https://doi.org/10.1200/PO.17.00073

3. Braun M, Aguilera AR, Sundarrajan A et al (2020) CD155 on Tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8(+) T cells. Immunity 53:805–823. https://doi.org/10.1016/j.immuni.2020.09.010. (e815)

4. Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. https://doi.org/10.1158/2159-8290.CD-12-0095

5. Chandrashekar DS, Karthikeyan SK, Korla PK et al (2022) UALCAN: an update to the integrated cancer data analysis platform. Neoplasia 25:18–27. https://doi.org/10.1016/j.neo.2022.01.001